Clinical Trials Browser

mirdametinib × Sarcoma × 90 days × Clear all

NCT06843967 2026-05-22

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Phase 1/2 Recruiting

Liposarcoma, Liposarcoma, Myxoid